安进2024年财报:营收增长19%,PCSK9单抗突破20亿美元,罕见病业务爆发

医药魔方Info
05 Feb

2月4日,安进公布2024年业绩,全年总收入334.24亿美元(+19%),其中产品收入320.26亿美元(+19%);全年研发费用58.78亿美元(+25%),占总收入的18%。安进将重点业务划分为综合内科疾病药物(General Medicine)、罕见病、炎症和肿瘤四大板块,其中普药板块贡献了100亿美元的收入并且实现了双位数增长。安进各业务板块代表性产品(亿美元)Repatha(依洛尤单抗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10